Structural Heart Devices Market By Product Type (Transcatheter Heart Valves; Surgical Heart Valves; Annuloplasty Rings; Occluders & Closure Devices; Accessories); By Procedure Type (Transcatheter Aortic Valve Replacement [TAVR]; Transcatheter Mitral Valve Repair [TMVR]; Surgical Aortic Valve Replacement [SAVR]; Left Atrial Appendage Closure [LAAC]; Septal Defect Closure); By Indication (Aortic Stenosis; Mitral Regurgitation; Atrial Septal Defects [ASD]; Patent Foramen Ovale [PFO]; Left Atrial Appendage Closure [LAAC]; Others); By End-User (Hospitals; Ambulatory Surgical Centers [ASCs]; Cardiac Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Structural Heart Devices Market Size & Overview

The Structural Heart Devices Market was valued at $14.4 billion in 2024 and is projected to reach $24.6 billion by 2030, growing at a CAGR of 9.3% during the forecast period. The market is driven by the increasing prevalence of structural heart diseases, advancements in transcatheter therapies & a growing preference for minimally invasive procedures.

 

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for nearly 17.9 million deaths globally each year, making them the leading cause of mortality. Among these, valvular heart diseases, congenital heart defects, and cardiomyopathies contribute significantly to the growing demand for structural heart interventions. Additionally, the Centers for Disease Control & Prevention (CDC) estimates that about 2.5% of the U.S. population suffers from valvular heart diseases, with aortic stenosis affecting nearly 12% of people over the age of 75.

 

Technological advancements in transcatheter aortic valve replacement (TAVR), mitral valve repair, left atrial appendage closure (LAAC) devices, and septal defect occluders are transforming treatment paradigms. The adoption of minimally invasive procedures has surged, as TAVR procedures are expected to surpass 290,000 cases globally by 2025, reducing the need for traditional open-heart surgeries. The market is also witnessing growth due to favorable reimbursement policies, expanding healthcare infrastructure in emerging economies & increasing clinical trial approvals for next-generation heart devices.

 

However, challenges such as high procedure costs, limited access to advanced cardiac care in low-income regions & stringent regulatory requirements may pose hurdles to market expansion. Despite these challenges, strong R&D investments, increasing awareness of structural heart diseases & the rising geriatric population are expected to drive sustained growth in the global Structural Heart Devices Market.

 

Structural Heart Devices Market Dynamics:

Market Drivers:

Rising Prevalence of Structural Heart Diseases – The increasing incidence of aortic stenosis, mitral regurgitation, and congenital heart defects is a major growth driver. According to the American Heart Association (AHA), over 5 million people in the U.S. are diagnosed with valvular heart disease annually, creating a strong demand for structural heart interventions such as transcatheter aortic valve replacement (TAVR) and mitral valve repair devices.

Growing Adoption of Minimally Invasive Procedures – Patients & healthcare providers are increasingly favoring transcatheter-based interventions over open-heart surgeries due to reduced hospital stays, lower complications, and faster recovery times. The PARTNER trials demonstrated that TAVR procedures reduced 2-year mortality rates by 25% compared to surgical valve replacement in high-risk patients, leading to wider adoption & market growth.

 

Market Restraints:

High Cost of Structural Heart Devices & Procedures – The cost of transcatheter valve replacement procedures can range between $30,000 - $50,000, making them inaccessible for many patients, especially in developing countries. Limited reimbursement policies in certain regions further exacerbate affordability concerns, restricting market penetration.

Regulatory Challenges and Approval Delays – Structural heart devices must undergo rigorous clinical trials & regulatory approvals before commercialization, which delays product launches and increases development costs. Boston Scientific's LOTUS Edge transcatheter valve system was withdrawn from the U.S. market in 2020 due to regulatory & manufacturing complexities, highlighting the difficulties companies face in this sector.

 

Market Opportunities:

Technological Advancements in Next-Generation Heart Valves – Innovations such as polymer-based heart valves, bioprosthetic valve technologies, and AI-driven imaging for procedural guidance are opening new opportunities. Companies like Medtronic and Edwards Lifesciences are investing heavily in next-generation transcatheter mitral and tricuspid valve repair and replacement technologies, aiming to improve durability and patient outcomes.

Expanding Market in Emerging Economies – The Asia-Pacific and Latin American markets are experiencing a surge in demand for structural heart interventions due to rising healthcare expenditure and increasing awareness. For instance, in China, TAVR procedures have grown by 30% annually, fueled by the expansion of healthcare infrastructure & government initiatives to promote advanced cardiac care.

 

Structural Heart Devices Market Segmentation: A Comprehensive Overview

By Product Type

• Transcatheter Heart Valves

• Surgical Heart Valves

• Annuloplasty Rings

• Occluders & Closure Devices

• Accessories

 

By Procedure Type

• Transcatheter Aortic Valve Replacement (TAVR)

• Transcatheter Mitral Valve Repair (TMVR)

• Surgical Aortic Valve Replacement (SAVR)

• Left Atrial Appendage Closure (LAAC)

• Septal Defect Closure

 

By Indication

• Aortic Stenosis

• Mitral Regurgitation

• Atrial Septal Defects (ASD)

• Patent Foramen Ovale (PFO)

• Left Atrial Appendage Closure (LAAC)

• Others

 

By End-User

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Cardiac Centers

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Structural Heart Devices Market Segment Analysis: Growth Trends Across Categories

By Product Type:

Leading Segment: Transcatheter Heart Valves

Transcatheter heart valves hold the largest market share in the structural heart devices market. This segment has gained prominence due to the increasing adoption of minimally invasive procedures like Transcatheter Aortic Valve Replacement (TAVR) for the treatment of aortic stenosis. The segment benefits from advancements in device technology, improved patient outcomes & the growing elderly population with high incidences of heart valve diseases. Transcatheter heart valves account for approximately 40-45% of the market share. The increasing shift toward non-surgical interventions is contributing to the dominance of this segment.

Fastest-Growing Segment: Occluders & Closure Devices

The occluders and closure devices segment is experiencing rapid growth, driven by the rising demand for minimally invasive interventions, particularly for left atrial appendage closure (LAAC) procedures and atrial septal defect (ASD) treatments. This segment is projected to grow at a CAGR of 9-11% over the forecast period, with increased adoption due to advancements in device efficacy & safety. Growing awareness about stroke prevention & improving procedures for the closure of heart defects are key factors driving this rapid growth.

 

By Procedure Type:

Leading Segment: Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter Aortic Valve Replacement (TAVR) remains the leading procedure type in the structural heart devices market. The adoption of TAVR continues to increase due to its effectiveness in treating aortic stenosis without the need for open-heart surgery. This minimally invasive procedure offers shorter recovery times & has become the preferred choice for elderly patients. TAVR is estimated to capture 50-55% of the market share, driven by its expanded approval for low-risk patients and its clinical success.

Fastest-Growing Segment: Left Atrial Appendage Closure (LAAC)

Left atrial appendage closure (LAAC) is the fastest-growing procedure type, with a CAGR of 12-14% due to the rising prevalence of atrial fibrillation (AF) & the need for stroke prevention. LAAC procedures are seeing increased adoption in patients who are not candidates for long-term anticoagulation therapy, making it a crucial option for stroke risk management in AF patients.

 

By Indication:

Leading Segment: Aortic Stenosis

Aortic stenosis is the leading indication for structural heart device procedures, driven by the high prevalence of this condition among the aging population. The demand for treatments like TAVR has grown significantly in recent years, especially among elderly patients who prefer non-invasive options. Aortic stenosis accounts for approximately 35-40% of the market share in structural heart devices.

Fastest-Growing Segment: Mitral Regurgitation

Mitral regurgitation is the fastest-growing indication segment in the structural heart devices market, growing at a CAGR of 8-10%. The increasing prevalence of mitral valve diseases, combined with the development of new transcatheter devices, is driving the growth in this segment. Additionally, the growing awareness & adoption of transcatheter mitral valve repair (TMVR) procedures contribute to this trend.

 

By End-User:

Leading Segment: Hospitals

Hospitals continue to dominate the structural heart devices market as the primary end-user, accounting for 60-65% of the market share. This segment is driven by the availability of advanced medical equipment, highly trained cardiologists & the capacity to handle complex procedures like TAVR, TMVR, and LAAC. The increasing preference for hospital-based interventions is due to better surgical support, patient monitoring, and post-operative care.

Fastest-Growing Segment: Ambulatory Surgical Centers (ASCs)

Ambulatory surgical centers (ASCs) are the fastest-growing end-user segment for structural heart devices, projected to grow at a CAGR of 7-9%. The rise of outpatient surgeries, particularly for less complex heart procedures like PFO and ASD closure, is driving the demand for ASCs. The adoption of minimally invasive techniques that allow for quicker recovery & reduced hospital stays is fueling growth in this segment.

 

By Region:

Leading Region: North America

North America holds the largest market share for structural heart devices, accounting for 40-45% of the market. The growth is driven by the advanced healthcare infrastructure, high adoption rates of innovative medical technologies & the rising incidence of cardiovascular diseases. The U.S., in particular, has a large patient population, with increasing numbers of elderly individuals requiring heart valve treatments and other structural heart device interventions.

Fastest-Growing Region: Asia-Pacific

The Asia-Pacific region is the fastest-growing region for the structural heart devices market, with a CAGR of 10-12%. This growth is fueled by the expanding healthcare access in countries like China, India, and Japan, along with increasing healthcare investments. The rising prevalence of heart diseases, greater awareness of advanced heart treatments, and improving healthcare infrastructure in the region are major factors contributing to this rapid growth.

 

Structural Heart Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 14.4 Billion
Revenue Forecast in 2030	USD 24.6 Billion
Overall Growth Rate	CAGR of 9.3% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Billion, CAGR (2024 – 2030)
Segmentation	By Product Type, By Procedure Type, By Indication, By End-User, By Geography
By Product Type	Transcatheter Heart Valves; Surgical Heart Valves; Annuloplasty Rings; Occluders & Closure Devices; Accessories
By Procedure Type	Transcatheter Aortic Valve Replacement (TAVR); Transcatheter Mitral Valve Repair (TMVR); Surgical Aortic Valve Replacement (SAVR); Left Atrial Appendage Closure (LAAC); Septal Defect Closure
By Indication	Aortic Stenosis; Mitral Regurgitation; Atrial Septal Defects (ASD); Patent Foramen Ovale (PFO); Left Atrial Appendage Closure (LAAC); Others
By End-User	Hospitals; Ambulatory Surgical Centers (ASCs); Cardiac Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of structural heart diseases, increasing demand for minimally invasive procedures, technological advancements in transcatheter heart valves
Pricing and Purchase Options	Customized options available

 

Key Players in the Structural Heart Devices Market

• Edwards Lifesciences Corporation

• Medtronic

• Abbott Laboratories

• Boston Scientific Corporation

• LivaNova PLC

• CryoLife, Inc. (now part of Artivion, Inc.)

• Braile Biomédica

• MicroPort Scientific Corporation

• Terumo Corporation

• JenaValve Technology, Inc.

 

Future Outlook

The future outlook for the Structural Heart Devices Market is highly optimistic, driven by the rising prevalence of valvular heart diseases, congenital heart defects, and the growing aging population. Technological advancements in transcatheter procedures, such as Transcatheter Aortic Valve Replacement (TAVR) & Transcatheter Mitral Valve Repair (TMVR), are revolutionizing the market by offering minimally invasive alternatives to traditional open-heart surgeries. The increasing adoption of robotic-assisted cardiac procedures, next-generation bioprosthetic valves, and AI-powered imaging systems is further enhancing procedural outcomes and reducing recovery times. Additionally, the expanding availability of percutaneous left atrial appendage closure (LAAC) devices for stroke prevention in atrial fibrillation patients is creating new growth opportunities. Regulatory approvals, favorable reimbursement policies, & strategic collaborations between medtech companies & healthcare providers will continue to shape the market. However, challenges such as high procedural costs, stringent regulatory requirements & limited access to advanced structural heart treatments in developing regions may hinder widespread adoption. Despite these challenges, continued R&D investments, clinical trials & technological innovations are expected to drive significant growth, positioning structural heart devices as a crucial component in the future of interventional cardiology and cardiovascular care.